Investment
Features
FeesSafety
Academy
More
Pluang+

Compare New York Times Co (NYT) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

New York Times CoTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

New York Times Co vs Vir Biotechnology Inc. Common Stock — how do they compare? New York Times Co trades at $66.9 (market cap $10.79B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: New York Times Co is far larger — about 6× Vir Biotechnology Inc. Common Stock's market cap, and New York Times Co pays a 1.38% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

NYTVIR
Market Cap
$10.79B$1.80B
Volume
2,034,8721,782,836
Sector
MediaHealth
52-Week High
$85.86$11.78
52-Week Low
$54.86$5.12
Typical Hold Time
82 Days0 Days
Enterprise Value
$10.18B$1.36B
Dividend Yield
1.38%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

New York Times Co

The New York Times Company (NYT) trades at $67.15, up 1.62% on the day, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82 billion in 2025, with net income reaching $344 million and a 12.17% margin. The company has beaten earnings estimates for the last three quarters, and analysts set a consensus price target of $81.50. Recent news includes a dividend declaration and ongoing litigation related to AI copyright issues.

Outlook is mixed: solid earnings growth and profitability support upside, but technical indicators and a shareholder lawsuit pose near-term risks. The stock offers value if it can maintain its growth trajectory, though investors should monitor legal developments and market sentiment closely.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NYT

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →